4D pharma Presents Late-Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
Genflow Biosciences Plc (LSE:GENF) Company Update
Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of ageing and diseases associated with advanced age, is pleased to
4d Pharma PLC (AIM:DDDD) Final Results
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
4d Pharma PLC (AIM:DDDD) MRx0518 + Keytruda – Primary endpoint met in RCC
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
4d Pharma PLC (AIM: DDDD) Participation in Chardan Microbiome Summit
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
4d Pharma PLC (AIM: DDDD) Parkinson’s trial receives FDA IND clearance
4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease
4d Pharma PLC (AIM: DDDD) Restatement of Interim Results to June 30, 2021
4D pharma to Restate Unaudited Interim Financial Statements for the Six-Month Period Ended June 30, 2021 to Correct Accounting for Warrants
Genflow Biosciences (GENF.L) First Day of Dealings
Admission to the Official List
Genflow Biosciences – Intention to Float on the London Stock Exchange
Genflow Biosciences Plc (“Genflow” or ” the Company”), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of ageing and diseases associated with
4d Pharma PLC (DDDD.L) Appoints John Doyle as Chief Financial Officer
Leeds, UK, January 4, 2022, – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic Products (LBPs), a novel class of drug derived
4d Pharma PLC (DDDD.L) Phase 1/2 asthma study Part A results
4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma